These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26137024)

  • 21. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
    Philips A; Radhakrishnan V; Ganesan P; Ganesan TS; Ramamurthy J; Dhanushkodi M; Sagar TG
    Indian J Hematol Blood Transfus; 2018 Oct; 34(4):618-622. PubMed ID: 30369730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
    Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasburicase improves hyperuricemia in infants with acute kidney injury.
    Hobbs DJ; Steinke JM; Chung JY; Barletta GM; Bunchman TE
    Pediatr Nephrol; 2010 Feb; 25(2):305-9. PubMed ID: 19936796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
    Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
    Pession A; Melchionda F; Castellini C
    Biologics; 2008 Mar; 2(1):129-41. PubMed ID: 19707436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
    Chiang J; Chan A; Lian T; Tay K; Quek R; Tao M; Lim ST
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):351-6. PubMed ID: 22151984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
    Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
    Kishimoto K; Kobayashi R; Hori D; Sano H; Suzuki D; Kobayashi K
    Anticancer Res; 2017 Oct; 37(10):5845-5849. PubMed ID: 28982910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
    Tatay VS; Castilla JD; Ponce JM; Hurtado JM; Cantero E; Abril ML
    An Pediatr (Barc); 2010 Feb; 72(2):103-10. PubMed ID: 20022572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasburicase for hyperuricemia in hemolytic uremic syndrome.
    Acosta AA; Hogg RJ
    Pediatr Nephrol; 2012 Feb; 27(2):325-9. PubMed ID: 22089328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
    Dinnel J; Moore BL; Skiver BM; Bose P
    Core Evid; 2015; 10():23-38. PubMed ID: 25610345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Toda Y; Ashizawa M; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Nagayama T; Umino K; Minakata D; Morita K; Yamamoto C; Hatano K; Sato K; Fujiwara SI; Ohmine K; Kanda Y
    Int J Hematol; 2024 Jun; 119(6):660-666. PubMed ID: 38575822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.